ProCE Banner Activity

(Neo) Adjuvant Therapy in HER2-Negative Early Breast Cancer Treatment Selection Tool

Tool

Learn how 5 experts incorporate the latest evidence on (neo) adjuvant therapy into the management of HER2-negative breast cancer using this Interactive Decision Support Tool.

Released: September 06, 2022

Expiration: September 05, 2023

Share

Faculty

Jame Abraham

Jame Abraham, MD, FACP

Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

Kevin Kalinsky

Kevin Kalinsky, MD, MS

Division Director, Medical Oncology
Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute at Emory University
Atlanta, Georgia

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Tiffany A. Traina

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Denise A. Yardley

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Additional Information

Program Medium

This program has been made available online.